EDRH
NRIX icon

Edmond de Rothschild Holding’s Nurix Therapeutics NRIX Stock Holding History

Edmond de Rothschild Holding’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Hold
90,000
– – 0.03% 240
2026
Q1 		$1.4M Buy
90,000
+10,000
+13% +$166K 0.02% 258
2025
Q4 		$1.52M Buy
+80,000
New +$1.15M 0.02% 268

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Edmond de Rothschild Holding's NRIX Position: Q2 2026 in Review

Edmond de Rothschild Holding held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 90,000 shares worth $2.18M. The position accounts for 0.03% of the portfolio, ranked #240.

Edmond de Rothschild Holding first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Edmond de Rothschild Holding held 90,000 shares of Nurix Therapeutics worth $2.18M as of Q2 2026.
  • Edmond de Rothschild Holding left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up 0.03% of Edmond de Rothschild Holding's portfolio in Q2 2026, its #240 holding.
  • Edmond de Rothschild Holding first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Edmond de Rothschild Holding's 13F filing for Q2 2026, filed 10 Aug 2026.